TrialJournal of neuro-oncology2019

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Kurt A Jaeckle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.